Optimal reporting of treatment outcome after external beam radiation therapy for prostate cancer

Ziaja, Ellen L.; Martínez, Álvaro; Horwitz, Eric M.; Vicini, Frank A.

doi:10.1016/s0360-3016(98)80451-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ben‐Josef et al developed a predictive model that included pretreatment PSA levels, post‐treatment PSA levels, PSA nadir, age, stage and grade. The authors concluded that their model had an overall accuracy rate for predicting failure of 81.8%, and sensitivity, specificity, and false‐negative rates of 87.2%, 79.6%, and 12.8%, respectively 92 …”

Section: Discussionmentioning

confidence: 99%

“…Several authors have combined these various pretreatment prognostic variables to develop models that predict out‐come 91–96 . Pisansky et al evaluated the results of RT alone in 500 patients and reported that pretreatment PSA level, Gleason score, and clinical T stage used in combination provided the most accurate model to predict success or failure following definitive RT 91 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

External beam radiation therapy for prostate cancer

Horwitz

Hanks

2000

CA: A Cancer Journal for Clinicians

View full text Add to dashboard Cite

Abstract6 During the past 35 years, external beam radiation therapy (RT) has been a mainstay in the management of prostate cancer and continues to be used in the treatment of almost one third of all patients receiving definitive therapy.7 Throughout the past decade, increasing numbers of patients receiving radiation have been treated with three-dimensional (3D) conformal rather than with conventional techniques. PROSTATE SPECIFIC ANTIGENThe development of the prostate specific antigen (PSA) test and its utilization as a screening tool, therapeutic measure, and prognostic indicator, have increased the number of patients diagnosed and subsequently treated for non-metastatic disease. More importantly, pretreatment PSA level has been shown to be the strongest independent predictor of treatment outcome (especially PSA control) after both surgery and radiation. [8][9][10][11] Biochemical disease-free survival [bNED-biochemical no evidence disease-control) is defined by a non-rising post-treatment PSA level, while a rising post-treatment PSA level now predicts failure many years before disease becomes clinically detectable.12-14 Appropriate use of pretreatment disease classification and serial post-treatment PSA levels allow accurate and meaningful assessments of various treatment modalities. 15Routine use of PSA measurement entered clinical practice in the late 1980s.C A C a n c e r J C l i n 2 0 0 0 ; 5 0 : 3 4 9 -3 7 5

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%